ViiV Healthcare's Cabenuva, a long-acting injectable HIV treatment, showed superior efficacy in maintaining viral load suppression compared to daily oral therapy in the LATITUDE phase III trial.
GSK's ViiV Healthcare division reports promising results for Cabenuva, a long-acting injectable HIV treatment. In the LATITUDE phase III trial, Cabenuva demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy for individuals facing adherence challenges. The DSMB recommended stopping randomisation and offering long-acting injectable therapy to participants in the oral therapy group.
February 21, 2024
4 Articles